Pregabalin and duloxetine in the practice of a psychiatrist. Frequently asked questions and doubts Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
pregabalin, duloxetine, SNRI, GABA, generalized anxiety disorder, depression, venlafaxine, benzodiazepine
Main Article Content
Abstract
Pregabalin was firstly used as an anti-epileptic drug, but later it there was found a new indication, especially generalized anxiety and neuropathic pain. Duloxetine was firstly used in the treatment of diabetic neuropathy, but in later years it was registered in the treatment of major depressive episodes and generalized anxiety. Both are very effective, but their use is limited by reimbursement recommendations. The paper presents situations in which the use of these drugs can give significant benefits.
Article Details
How to Cite
Sobów, T. (2019). Pregabalin and duloxetine in the practice of a psychiatrist. Frequently asked questions and doubts. Medycyna Faktow (J EBM), 12(2(43), 132-135. https://doi.org/10.24292/01.MF.0219.7
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
2. Cipriani A., Koesters M., Furukawa T.A., et al.: Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2014; 10: CD006533.
3. Girardi P., Pompili M., Innamorati M. et al.: Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum. Psychopharmacol. 2009; 24(3): 177-190.
4. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006; 188: 346-353.
5. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
6. Dunner D.L., Goldstein D.J., Mallinckrodt C. et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety 2003; 18: 53-61.
7. Fava M., Mallinckrodt C.H., Detke M.J. et al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65(4): 521-530.
8. Tokuoka H., Nishihara M., Fujikoshi S. et al.: Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine. Neuropsychiatr. Dis. Treat. 2017; 13: 2457-2467.
9. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13(3): 227-235.
10. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
11. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G. et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
12. Hidalgo R.B., Tupler L.A., Davidson J.R.: An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007; 21: 864-872.
13. Bandelow B., Sher L., Bunevicius R. et al.: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012; 16: 77-84.
14. Baldwin D.S., Anderson I.M., Nutt D.J. et al.: Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J. Psychopharmacol. 2014; 28(5): 403-439.
15. Katzman M.A., Bleau P., Blier P. et al.: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive- compulsive disorders. BMC Psychiatry 2014; 14(supl. 1): S1.
2. Cipriani A., Koesters M., Furukawa T.A., et al.: Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2014; 10: CD006533.
3. Girardi P., Pompili M., Innamorati M. et al.: Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum. Psychopharmacol. 2009; 24(3): 177-190.
4. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006; 188: 346-353.
5. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
6. Dunner D.L., Goldstein D.J., Mallinckrodt C. et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety 2003; 18: 53-61.
7. Fava M., Mallinckrodt C.H., Detke M.J. et al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65(4): 521-530.
8. Tokuoka H., Nishihara M., Fujikoshi S. et al.: Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine. Neuropsychiatr. Dis. Treat. 2017; 13: 2457-2467.
9. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13(3): 227-235.
10. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
11. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G. et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
12. Hidalgo R.B., Tupler L.A., Davidson J.R.: An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007; 21: 864-872.
13. Bandelow B., Sher L., Bunevicius R. et al.: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012; 16: 77-84.
14. Baldwin D.S., Anderson I.M., Nutt D.J. et al.: Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J. Psychopharmacol. 2014; 28(5): 403-439.
15. Katzman M.A., Bleau P., Blier P. et al.: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive- compulsive disorders. BMC Psychiatry 2014; 14(supl. 1): S1.